Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.
J Exp Med
; 217(9)2020 09 07.
Article
en En
| MEDLINE
| ID: mdl-32678432
ABSTRACT
An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Infecciones por Coronavirus
/
Pandemias
/
Betacoronavirus
Límite:
Humans
Idioma:
En
Revista:
J Exp Med
Año:
2020
Tipo del documento:
Article
País de afiliación:
Alemania